Methods for obtaining reliable and reproducible results in studies of Candida biofilms formed in vitro

Biofilm formation is one of the most important attributes for virulence in Candida species and contributes to increased resistance to antifungal drugs and host immune mechanisms. These features have led to the development of several methodologies to reproduce a sessile community in vitro that can be used to study the development of a biofilm, its interaction with other microorganisms and the environment, and its susceptibility to available antifungal agents and also to search for new therapy strategies. The purpose of this review is to describe the most commonly used methods to study Candida biofilms in vitro, to discuss the benefits and limitations of the different methods to induce biofilm formation, and to analyse the architecture, viability and growth kinetics of Candida biofilms. © 2013 Blackwell Verlag GmbH.

Photodynamic inactivation of clinical isolates of Candida using Photodithazine

This study evaluated the photodynamic inactivation (PDI) mediated by Photodithazine® (PDZ) against 15 clinical isolates of Candida albicans, Candida glabrata and Candida tropicalis. Each isolate, in planktonic and biofilm form, was exposed to PDI by assessing a range of PDZ concentrations and light emitting diode fluences. Cell survival of the planktonic suspensions was determined by colony forming units (CFU ml-1). The antifungal effects of PDI against biofilms were evaluated by CFU ml-1 and metabolic assay. Data were analyzed by non-parametric tests (α = 0.05). Regardless of the species, PDI promoted a significant viability reduction of planktonic yeasts. The highest reduction in cell viability of the biofilms was equivalent to 0.9 log10 (CFU ml-1) for C. albicans, while 1.4 and 1.5 log10 reductions were obtained for C. tropicalis and C. glabrata, respectively. PDI reduced the metabolic activity of biofilms by 62.1, 76.0, and 76.9% for C. albicans, C. tropicalis, and C. glabrata, respectively. PDZ-mediated PDI promoted significant reduction in the viability of Candida isolates. © 2013 Taylor & Francis.

Presença de Candida, staphylococcus, enterobacteriaceae e pseudomonadaceae na cavidade bucal de pacientes HIV positivos

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Atividade antimicrobiana de Mentha piperita L. sobre leveduras do gênero Candida

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Efeitos da terapia fotodinâmica sobre cepas de Candida isoladas de pacientes submetidos à antibioticoterapia prolongada

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Estudo da atividade antifúngica e perfil de expressão de proteínas em leveduras do gênero Candida após tratamento com extratos de Kielmeyera rubriflora

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Colonização e identificação de Streptococcus grupo mutans e candida ssp. em lesões de cárie associadas ou não a síndrome da cárie de mamadeira

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Efeitos de diferentes tratamentos a plasma e de variações na coleta, preparo e pré-condicionamento com saliva na adesão de Candida a uma resina para a base de prótese

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Efeitos da terapia fotodinâmica na expressão dos genes SAP5, LIP9 e PLB2 em Candida albicans

Pós-graduação em Biopatologia Bucal - ICT

Selective photoinactivation of Candida albicans in the non-vertebrate host infection model Galleria mellonella

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Candidose experimental e recuperação de candida albicans na cavidade bucal de ratas ovariectomizadas

Pós-graduação em Biopatologia Bucal - ICT

Evaluation of caries-associated virulence of biofilms from Candida albicans isolated from saliva of pediatric patients with sickle-cell anemia

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Antifungal activity of extracts and isolated compounds from Buchenavia tomentosa on Candida albicans and non-albicans

Aim: This study aimed to evaluate the antifungal activity of Buchenavia tomentosa extract and bioactive compounds on six Candida species. Materials & methods: The antimicrobial activity of extract was evaluated using standard strains and clinical isolates. Cytotoxicity was tested in order to evaluate cell damage caused by the extract. Extract was chemically characterized and the antifungal activity of its compounds was evaluated. Results: Extract showed antifungal activity on Candida species. Candida non-albicans were more susceptible than Candida albicans. Low cytotoxicity for extract was observed. The isolated compounds presented antifungal activity at least against one Candida spp. and all compounds presented antifungal effect on Candida glabrata. Conclusion: Extracts from Buchenavia tomentosa showed promising antifungal activity on Candida species with low cytotoxicity. Gallic acid, corilagin and ellagic acid showed promising inhibitory activity on Candida glabrata.

Candida species biofilm and Candida albicans ALS3 polymorphisms in clinical isolates

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model

Candida albicans is the most frequent cause of fungal keratitis in temperate regions. Caspofungin has potent activity against Candida spp. in a variety of clinical settings. Little is known, however, about its activity against fungal keratitis. We compared the efficacy of topical caspofungin with that of topical amphotericin B (AMB) in a rabbit model of experimental keratomycosis. Keratitis was induced with a standardized inoculum of Candida albicans (SC 5314) placed on the debrided cornea. Twenty-four hours after infection, animals were randomly assigned to treatment with 0.15% caspofungin, 0.5% caspofungin, 0.15% AMB, and a saline control (n = 12 rabbits in each group). For the first 12 h, treatment was repeated every 30 min and, after a 12-h pause, was resumed at hourly intervals for another 12 h. The animals were examined and killed 12 h after administration of the last dose. Treatment effects were evaluated by clinical assessment, fungal culture, and histopathology. Drug treatment significantly reduced corneal fungal recovery from 3.78 log10 CFU in saline-treated animals to 2.97, 1.76, and 1.18 log10 CFU in animals treated with 0.15% caspofungin, 0.5% caspofungin, and 0.15% AMB, respectively. By histopathology, the mean hyphal density was significantly lower in the corneas of treated animals than in those of the controls; there was no difference in hyphal densities between the different treatment groups. The depth of corneal invasion was not significantly reduced by the antifungal treatments. By clinical assessment, keratitis progressed in animals treated with saline, whereas disease progression was inhibited by all drug treatment regimens. In our rabbit model, 0.5% caspofungin was as effective as 0.15% AMB for the topical treatment of Candida keratitis. The potential clinical efficacy of caspofungin awaits further investigation.